A two-stage design with two co-primary endpoints  by Song, James X.
lable at ScienceDirect
Contemporary Clinical Trials Communications 1 (2015) 2e4Contents lists avaiContemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctcA two-stage design with two co-primary endpoints
James X. Song
100 Tice Blvd, Woodcliff Lake, NJ 07677, USAa r t i c l e i n f o
Article history:
Received 8 June 2015
Received in revised form
16 August 2015
Accepted 24 August 2015
Available online 1 October 2015
Keywords:
Phase II oncology trials
Co-primary endpoints
Two-stage designE-mail address: james_song@eisai.com.
http://dx.doi.org/10.1016/j.conctc.2015.08.002
2451-8654/© 2015 The Author. Published by Elseviera b s t r a c t
Two-stage designs are commonly used in phase II oncology trial to mitigate the risk of exposing patients
to an inefﬁcacious drug. Typically, the decision of moving into stage 2 enrollment is made based on
response rate in stage 1 patients; and trials are designed in the hypothesis testing framework. When the
primary objective of a trial involves more than one efﬁcacy endpoints it is desirable to extend the two-
stage design to a setting that accommodates two hypotheses while controlling overall type I and II errors
(a and b). In this manuscript, we propose a simple method of searching stopping boundaries of both
hypotheses simultaneously that satisfy a and b constrains using binomial distribution. Several design
characteristics of these selected boundaries are further examined in order to choose the most desirable
design based on an objective function. Simulation is used to conﬁrm the results. A trial design in met-
astatic breast cancer where both response rate and health-related quality of life are of interest is used as
an example of the application of the proposed method. In conclusion, the proposed design is an
extension of Simon Two-Stage Design. It can be applied to phase II oncology trials with two independent
co-primary efﬁcacy endpoints.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The objective of a phase II oncology trial is to assess the anti-
tumor activity of a new drug and thus to determine whether it
warrants further study in the phase III setting. It is common not to
include a control arm in these trials in order to gain evidence on the
efﬁcacy and safety as quickly as possible and to focus on a relatively
rapidly observable endpoint such as tumor objective response rate
(ORR). An interim futility analysis is often desirable to limit the
number of patients exposed in case of low activity.
Several authors [1e4] proposed two-stage designs in which a
ﬁxed number of patients are accrued in stage 1 (n1) and in total (n).
The study is continued into stage 2 only when interim boundary
(r1) is crossed. Typically, one tests the null hypothesis H0: p ¼ p0
against the alternative HA: p ¼ pA, where p is the probability of
response, p0 is the response rate below which one considers the
drug insufﬁciently active and pA is the assumed response rate of the
new drug. In a well-known two-stage design, Simon proposed
method of choosing n1, n, r1 and boundary at ﬁnal analysis (r) via
binomial distribution when p0, pA, type I and II errors (a and b) are
speciﬁed. A numerical search is conducted to ﬁnd all designs that
have actual a and b no more than speciﬁed levels. Among them,Inc. This is an open access article uSimon suggested the design that minimizes the expected sample
size under p0 (optimal) and the one that minimizes the maximum
sample size (minimax).
A number of extensions to Simon Two-Stage Design have been
proposed. Green and Dahlberg [5] proposed several approaches to
adapting interim stopping rules when the actual sample size is not
the planned size. Jung et al. [6] developed a family of two-stage
designs that are admissible according to a Bayesian loss function
in which Simon optimal and minimax designs are special cases.
Sargent et al. [7] extended hypothesis testing in two-stage design to
three possible outcomes: reject H0, reject HA or reject neither. Jones
and Holmgren [8] modiﬁed the design to allow an opportunity to
assess whether a drug is active in a disease population as awhole or
in a targeted subset of biomarker positive patients. Bayesian two-
stage designs have been proposed by a number of authors. Sam-
bucini [9] proposed method of deriving an adaptive two-stage
design, where the second stage sample size is not selected in
advance, but depends on the ﬁrst stage results via Bayesian pre-
dictive design. Tan andMachin [10] proposed new Bayesian designs
which allow for the incorporation of relevant prior information and
the presentation of the trial results in a manner which is more
intuitive and helpful.
In oncology trials, besides ORR, efﬁcacy outcomes such as
disease control rate (DCR), deﬁned as percentage of patients with
best overall response of stable disease or better; andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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week PFS) are also useful measures of anticancer activities.
Various measures of health-related quality of life (HRQL),
including European Organisation for the Research and Treatment
of Cancer Quality of Life Questionaire Core 30 (EORTC QLQ-C30),
Functional Assessment of Cancer Therapy e General (FACT-G)
and their disease speciﬁc modules are widely accepted as end-
points in clinical trials. Consequently, achieving improvement or
maintaining stability in HRQL measures by a speciﬁc time point
could also be considered as clinical beneﬁt. In addition, dichot-
omous outcomes based on pharmacodynamic markers, dosing
feasibility or a subgroup of special interest are often included in
one of the primary objectives of the phase II trials. Therefore, it is
desirable to extend Simon Two-Stage Design to a setting that
accommodates two null hypotheses. In this manuscript, we
propose a two-stage design that includes a 2nd hypothesis, H0:
p0 ¼ p00 vs. HA: p0 ¼ p0A, such that both hypothesis tests are carried
out within two-stage design framework while controlling overall
type I and II errors.2. Methods
In the current design, we describe a method of searching for
boundaries of the 1st hypothesis (r1 and r) and the 2nd hypothesis
(r01and r
0) simultaneously using binomial distribution. The trial will
move into stage 2 if the number of successes in the ﬁrst endpoint
(x1) is greater than r1 or the number of successes in the second
endpoint (y1) is greater than r01 in the ﬁrst n1 patients. In the ﬁnal
analysis of n patients, the ﬁrst H0 will be rejected if more than r
successes are observed in the ﬁrst endpoint (x); and the second H0
will be rejected if more than r0 successes are observed in the second
endpoint (y). To better illustrate the proposed approach, we assume
n1 and n are given since both are often pre-ﬁxed due to operational
constrain and logistic convenience.
This design differs from combining two independent Simon
Two-Stage Designs since a different interim decision rule is used.
Instead of evaluating each endpoint independently and accepting
H0 when it fails to pass interim boundary, hypothesis tests in both
endpoints are carried out at ﬁnal analysis as long as stage 1
boundary is crossed in at least one endpoint. This testing strategy is
more intuitive and ﬂexible than making separate interim decisions
within each endpoint. Otherwise, one may face the dilemma of
accepting H0 when failing to pass stage 1 boundary whereas the
ﬁnal boundary is crossed.
According to the decision rules described above, the probability
of accepting H0s is P(x1 r1 ∩ y1 r01) þ P(x  r ∩ y  r0jx1
> r1 U y1> r01). Under the independence assumption of two end-
points, it is expressed as
Bðr1; p;n1ÞB

r01;p
0;n1
þ
Xminðn1;rÞ
x¼0
Xminðn1;r0Þ
y¼0
bðx; p;n1ÞBðr  x; p;n
 n1Þbðy; p0;n1ÞBðr0  y; p0;n
 n1Þ for ðx; yÞ2fx> r1 or y> r01g
(1)
where b and B denote the binomial density and cumulative func-
tions. Using Eq. (1), given n1, n, p, p0, any sets of boundaries r1, r, r01
and r0 that satisfy a and b can be obtained.
For a selecteddesign, theprobabilityof acceptingH0 of a particular
endpoint can be calculated. For example, P(accept H0: p ¼
p0) ¼ P(x1 r1 ∩ y1 r01) þ P(x rjx1> r1 U y1> r01) ¼ P(x1 r1 ∩ y1
 r01) þ P(x  rjx1> r1) þ P(x  rjx1 r1 ∩ y1> r01). Under the inde-
pendence assumption, it is written asBðr1; p;n1ÞB

r01; p
0;n1
þ
Xminðn1 ;rÞ
x¼r1þ1
bðx; p;n1ÞBðr  x; p;n n1Þ
þ
Xr1
x¼0
bðx;p;n1ÞBðr  x; p;n n1Þ

1 Br01; p0;n1

(2)
The type I error in the ﬁrst hypothesis, a1, is calculated according
to Eq. (2) when p ¼ p0 and p0 ¼ p00. The corresponding type II error,
b1, is calculated when p ¼ pA and p0 ¼ p0A. The type I and II errors in
the second hypothesis (a2 and b2) can be obtained similarly.
Further statistical criteria need to be deﬁned using type I and II
errors of each endpoint calculated in Eq. (2) in order to select an
appropriate design from those satisfying Eq. (1). Here, we regard an
ideal design as one with comparable powers in the two hypothesis
tests both at interim and ﬁnal analyses, while controlling type I
errors in each endpoint. Since overall type I error of each endpoint
is controlled in Eq. (1) (i.e. <a), additional type I error control is
achieved by excluding designs with unacceptable high type I errors
at interim analysis (a11 and a21). Next, a function of type II errors at
the interim analysis (b11 and b21) and overall type II errors (b1 and
b2) is evaluated. Such an objective function can be deﬁned as
Sðb1;b2; b11; b21Þ ¼ w

b21 þ b22
1=2 þ ð1wÞ

b211 þ b221
1=2
(3)
where w is a constant weight between 0 and 1. Hence, S(b1, b2, b11,
b21) is a weighted function of square root of sum of square of type II
errors at ﬁnal and square root of sum of square of type II errors at
interim analysis. The goal is to identify designs that minimize type
II errors of each endpoint at ﬁnal and interim analyses. w can be set
between ½ and 1 (e.g. 2/3) since typically minimizing the ﬁrst part
of function S is of most importance, therefore, carrying more
weight. The design with the minimal S is recommended.
3. An example
The method was motivated by a planned phase II trial in met-
astatic breast cancer. ORR and percentage of patients without
deterioration in Global Health Status of EORTC QLQ-C30 (GHS) in
the ﬁrst two cycles of treatment were two key efﬁcacy variables of
interest. We set up H0: ORR ¼ 5% vs. HA: ORR ¼ 15% and H0:
GHS ¼ 45% vs. HA: GHS ¼ 60%. Sample sizes were determined be-
forehand as n1¼15 and n¼ 55. Using Eq. (1), 636 sets of boundaries
satisfying overall a 0.05 and b 0.2 were identiﬁed. Upon further
inspection, some of the designs showed undesirable characteristics
such as extreme high type I or II errors in one hypothesis test and
extreme low probability of early termination after the ﬁrst stage
under null hypotheses. Therefore, designs with overly high type I
errors at interim analysis (a11 > 0.7 or a21 > 0.7) were excluded. To
further select a sensible design, S(b1, b2, b11, b21) with w ¼ 2/3 was
calculated for the remaining 253 designs. The one with smallest
value of S was chosen (r1 ¼ 0, r ¼ 6, r01 ¼ 7 and r0 ¼ 31). With these
boundaries, the probabilities of early stopping under the null and
alternative hypotheses were estimated as 0.3028 and 0.0186,
respectively. The expected sample sizes under the null and alter-
native hypotheses were 43 and 54, respectively. Within each test,
a1 ¼ 0.0183 and b1 ¼ 0.2701 in testing the 1st hypothesis of ORR;
and a2 ¼ 0.0311 and b2 ¼ 0.3440 in testing the 2nd hypothesis of
GHS. The overall trial-wise a and b were 0.0488 and 0.1001,
respectively.
Simulation was used to conﬁrm the results. One hundred
thousand trials were run using random samples generated based
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rules described in theMethods sectionwere applied to simulate the
trial results. The simulation results were very close to the ones
described above (within 1% error).
4. Conclusions
A simple approach for modiﬁcation of the Simon Two-Stage
Design is proposed to accommodate phase II trials where two co-
primary endpoints are of interest. Sample sizes in stage 1 and to-
tal are pre-speciﬁed to simplify the decision making. But the al-
gorithm can be easily expanded to ﬁnd designs for given a and b in
a ﬁxed range of n1 and n. As illustrated in the example, it is rec-
ommended to ﬁrst identify all the designs that satisfy trial-wise a
and b in Eq. (1). Subsequent selection of the stopping boundary
should be made based on other operating characteristics that are
calculated using exact binomial probabilities. Since two hypothesis
tests are included, admissible designs including Simon optimal and
minimax designs developed in one hypothesis testing [6] are not
applicable. Instead of balancing between expected sample size and
maximum sample size, it is desirable to have comparable type I or II
errors between two tests, so each hypothesis can be properly
tested. For trials having different treatment effects between the two
endpoints, as shown in the example, it may not be an easy objective
to achieve. Given the numerous parameters involved, we ﬁrst
screened out the designs with high type I errors at interim, then
attempted to deﬁne an objective function S(b1, b2, b11, b21) to select
the design that minimizes the type II errors. One may calculate S(b1,
b2, b11, b21) with several different weights in order to better assess
its impact; and therefore to choose the most appropriate design. If
the primary objective of the design is to stop the trial early in case
of ineffective treatment (type I error control), rather than maxi-
mizing powers, a different strategy of design selection should beemployed. One might ﬁrst screen out the designs with unaccept-
able high type II errors at interim analysis, then select a designwith
minimal value of S0(a1, a2, a11, a21), where S0(a1, a2, a11, a21), a
function of type I errors, can be set up similar as S(b1, b2, b11, b21).
The approach assumes independence of two test statistics in the
endpoints. In clinical trial, it is not uncommon that the two efﬁcacy
endpoints of interest are correlated. Future work will include
extension of proposed method to two correlated endpoints.
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